Treovir Inc

Treovir was established in 2019 to develop and commercialize G207, an oncolytic HSV virus for the treatment of pediatric brain tumors. A Phase 1 clinical trial has been completed demonstrating strong evidence of safety and efficacy. Treovir will launch a Phase 2 clinical study for G207 in 2023 that is designed to seek market approval to treat pediatric patients with recurrent pediatric gliomblastoma. Pediatric Brain Tumors are the most common form of solid tumor in children. More than 3,400 children are diagnosed every year. Outcomes for children with high-grade glioma are poor despite surgery, radiation and chemotherapy, which produce devastating neurotoxicities in a child’s developing brain. There has been a complete lack of therapeutic advances in the past 15 years, and the median survival at tumor recurrence is less than 6 months. The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses. In a Phase 1 clinical trial in 12 patients, G207 therapy saw Improved overall survival of 12.2 months versus 5.6 months for historical trials. There was also a dramatic safety advantage with no serious adverse events observed. Significantly, evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot” was also observed indicating the body's own immune system was activated against the tumors.